• Contact info@abtriva.com for inquiries and orders.
  • Chinese (Simplified)

  • English

  • German

  • Korean

  • Spanish

United States (English / $ USD)

Recombinant Human Immunoglobulin lambda-like polypeptide 1 (IGLL1)

ACP24121

Number
Order Exclusive Products Now

Request a Quote
High Purity LevelsPrecision and ReliabilityCustomization Options

Specifications


Cat.No ACP24121 Target NameIGLL1
FormLyophilized powderExpression SystemCustom Production. Please inquire and provide the desire expression system.
Expression Range38-213Protein LengthFull Length of Mature Protein
Purity>85% (SDS-PAGE)Storage Buffer5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, Liquid form: default storage buffer is Tris/PBS-based buffer, pH 8.0.

Immunogen Information


Target SpeciesHumanUniprot IDP15814
Background Information
  • Uniprot Id

    P15814

  • Target Species

    Human

  • Target Name

    IGLL1

  • Target Full Name

    Immunoglobulin lambda-like polypeptide 1

  • Target Function

    Critical for B-cell development.

  • Target Involvement

    Agammaglobulinemia 2, autosomal recessive (AGM2)

  • Target Subcellular Location

    Endoplasmic reticulum. Secreted.

  • Target Tissue Specificity

    Expressed only in pre-B-cells and a special B-cell line (which is surface Ig negative).

  • Target Synonyms

    14.1; AGM2; CD179 antigen-like family member B; CD179b; CD179b antigen; Ig lambda 5 ; Ig lambda-5; IGL1 ; IGL5; IGLJ14.1 ; IGLL ; Igll1; IGLL1_HUMAN; IGO ; IGVPB ; Immunoglobulin lambda like polypeptide 1 precursor; Immunoglobulin lambda-like polypeptide 1; Immunoglobulin omega polypeptide; Immunoglobulin omega polypeptide chain; Immunoglobulin related protein 14.1 ; Immunoglobulin-related protein 14.1; Lambda5; Pre B lymphocyte specific protein 2 ; VPREB2

Inquire Recombinant Human Immunoglobulin lambda-like polypeptide 1 (IGLL1) Now



AbTriva respects your privacy and protects your personal data in accordance with AbTriva. For more information, please see our data protection statement. *

Notification